FDA Clearance Tracker · P140003-S102
Impella 2.5, Impella CP, Impella CP with SmartAssist, Impella 5.0, Impella LD
Last checked: Nov 20, 2026Latest source record: Aug 18, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Aug 18, 2022
Approved
Time to decision
29 days
Received Jul 20, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P140003-S102
- Device name
- Impella 2.5, Impella CP, Impella CP with SmartAssist, Impella 5.0, Impella LD
- Applicant
- Abiomed, Inc.
- Applicant location
- Danvers, MA
- Received
- Jul 20, 2022
- Decided
- Aug 18, 2022
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P140003
Device type
- Device class
- Class III
- Specialty
- Cardiology
FDA's approval statement
As written in FDA's record.
Approval of the protocol for the post-approval study (PAS) protocol.
Source documents
Other decisions for Abiomed, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K252766 · Decided Oct 8, 2025 · 40 days after receipt
Device type: Introducer, Catheter (DYB) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.